Inspire Investing LLC Sells 25,259 Shares of Geron Co. (NASDAQ:GERN)

Inspire Investing LLC decreased its holdings in shares of Geron Co. (NASDAQ:GERN) by 23.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,660 shares of the biopharmaceutical company’s stock after selling 25,259 shares during the quarter. Inspire Investing LLC’s holdings in Geron were worth $350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of GERN. Farallon Capital Management LLC bought a new stake in Geron during the 1st quarter valued at $24,734,000. Affinity Asset Advisors LLC bought a new stake in Geron during the 1st quarter valued at $8,250,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Geron by 999.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after purchasing an additional 1,877,184 shares during the period. Altitude Crest Partners Inc. bought a new position in shares of Geron in the first quarter worth $5,054,000. Finally, Vanguard Group Inc. increased its holdings in shares of Geron by 4.6% in the first quarter. Vanguard Group Inc. now owns 29,869,287 shares of the biopharmaceutical company’s stock worth $98,569,000 after purchasing an additional 1,304,713 shares during the period. Institutional investors own 73.71% of the company’s stock.

Geron Stock Down 9.1 %

Shares of NASDAQ:GERN opened at $4.28 on Tuesday. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34. The firm has a fifty day moving average of $4.55 and a 200 day moving average of $4.06. The firm has a market capitalization of $2.54 billion, a PE ratio of -12.23 and a beta of 0.50. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The company’s revenue was up 2941.4% on a year-over-year basis. As a group, research analysts anticipate that Geron Co. will post -0.34 EPS for the current fiscal year.

Insider Buying and Selling at Geron

In other Geron news, COO Andrew J. Grethlein sold 674,348 shares of the company’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $4.56, for a total transaction of $3,075,026.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

GERN has been the topic of several research analyst reports. StockNews.com raised shares of Geron to a “sell” rating in a report on Monday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Geron in a report on Thursday, August 8th. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Geron in a report on Friday, August 9th. Finally, Leerink Partners initiated coverage on shares of Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron presently has a consensus rating of “Moderate Buy” and an average target price of $7.06.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.